Unlocking new ways to overcome drug resistance and enhance existing treatments.
A New Genetic Logic for Cancer Therapy
Targeted therapies have transformed precision oncology, but they lack the long-term durability needed to cure advanced tumors.
At Red Ace, we take a different approach: we reprogram tumors from the inside out to create entirely new therapeutic opportunities.
By rewiring cancer cells with synthetic vulnerabilities, our platform can overcome resistance and enable treatments that last.
Why it Works
We use tumor-targeting vectors to deliver gene circuits that reprogram cancer cells.
Then, engineered cells work like a Trojan horse, re-engineering the tumor before delivering the final blow.
We’ve pioneered a new therapeutic platform called selection gene drive technology.
Using tumor-targeted viral vectors, we selectively deliver therapeutic gene circuits directly into cancer cells. These circuits work in combination with existing treatments to rewire tumors with new, synthetic vulnerabilities.
Once the tumor is reprogrammed, we activate these vulnerabilities to eliminate resistant cancer cells—delivering a powerful, two-step strategy designed to prevent relapse.
Partner With Us
Let’s Build the Future of Cancer Therapy
If you're an investor or strategic partner interested in advancing
the next generation of gene therapies, we’d love to hear from you.
